helius medical technologies - HSDT

HSDT

Close Chg Chg %
2.03 -0.05 -2.46%

Closed Market

1.98

-0.05 (2.46%)

Volume: 451.08K

Last Updated:

Apr 14, 2026, 4:00 PM EDT

Company Overview: helius medical technologies - HSDT

HSDT Key Data

Open

$2.12

Day Range

1.96 - 2.12

52 Week Range

1.61 - 265.50

Market Cap

$111.72M

Shares Outstanding

55.03M

Public Float

30.26M

Beta

0.91

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$489.31

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

492.96K

 

HSDT Performance

1 Week
 
7.41%
 
1 Month
 
-3.79%
 
3 Months
 
-38.48%
 
1 Year
 
-99.02%
 
5 Years
 
-100.00%
 

HSDT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About helius medical technologies - HSDT

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

HSDT At a Glance

Solana Co.
642 Newtown Yardley Road
Newtown, Pennsylvania 18940
Phone 1-215-944-6100 Revenue 6.02M
Industry Medical Specialties Net Income -40,890,000.00
Sector Health Technology 2025 Sales Growth 1,057.115%
Fiscal Year-end 12 / 2026 Employees 21
View SEC Filings

HSDT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 10.59
Price to Book Ratio 0.42
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.672
Enterprise Value to Sales 9.379
Total Debt to Enterprise Value N/A

HSDT Efficiency

Revenue/Employee 286,523.81
Income Per Employee -1,947,142.857
Receivables Turnover N/A
Total Asset Turnover 0.039

HSDT Liquidity

Current Ratio 10.33
Quick Ratio 9.958
Cash Ratio 2.414

HSDT Profitability

Gross Margin 91.69
Operating Margin -351.022
Pretax Margin -679.575
Net Margin -679.575
Return on Assets -26.598
Return on Equity -27.082
Return on Total Capital -13.589
Return on Invested Capital -27.082

HSDT Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Helius Medical Technologies - HSDT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
787.00K 644.00K 520.00K 6.02M
Sales Growth
+50.77% -18.17% -19.25% +1,057.12%
Cost of Goods Sold (COGS) incl D&A
644.00K 745.00K 642.00K 500.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 306.00K 162.00K 60.00K
Depreciation
- 125.00K 45.00K 36.00K
Amortization of Intangibles
- 181.00K 117.00K 24.00K
COGS Growth
+29.32% +15.68% -13.83% -22.12%
Gross Income
143.00K (101.00K) (122.00K) 5.52M
Gross Income Growth
+495.83% -170.63% -20.79% +4,622.13%
Gross Profit Margin
+18.17% -15.68% -23.46% +91.69%
2022 2023 2024 2025 5-year trend
SG&A Expense
14.90M 12.17M 13.74M 26.64M
Research & Development
4.26M 2.94M 3.66M 3.51M
Other SG&A
10.64M 9.23M 10.08M 23.13M
SGA Growth
-17.89% -18.35% +12.93% +93.86%
Other Operating Expense
- - - -
-
Unusual Expense
(2.27M) (2.81M) (2.94M) (187.08M)
EBIT after Unusual Expense
(12.49M) (9.46M) (10.92M) 165.96M
Non Operating Income/Expense
(1.58M) 612.00K (820.00K) (11.03M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 195.82M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 195.82M
-
Interest Capitalized
- - - -
-
Pretax Income
(14.07M) (8.85M) (11.74M) (40.89M)
Pretax Income Growth
+22.39% +37.11% -32.68% -248.24%
Pretax Margin
-1,788.06% -1,374.22% -2,258.08% -679.57%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(14.07M) (8.85M) (11.74M) (40.89M)
Minority Interest Expense
- - - -
-
Net Income
(14.07M) (8.85M) (11.74M) (40.89M)
Net Income Growth
+22.39% +37.11% -32.68% -248.24%
Net Margin Growth
-1,788.06% -1,374.22% -2,258.08% -679.57%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(14.07M) (8.85M) (11.74M) (40.89M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.07M) (8.85M) (11.74M) (40.89M)
EPS (Basic)
-39097.1251 -10918.92 -3249.8925 -1.8546
EPS (Basic) Growth
+85.87% +72.07% +70.24% +99.94%
Basic Shares Outstanding
359.9242391 810.5199979737 3.61K 22.05M
EPS (Diluted)
-39097.1251 -10918.92 -3249.8925 -1.8546
EPS (Diluted) Growth
+85.87% +72.07% +70.24% +99.94%
Diluted Shares Outstanding
359.9242391 810.5199979737 3.61K 22.05M
EBITDA
(14.45M) (12.11M) (13.80M) (21.12M)
EBITDA Growth
+18.57% +16.23% -14.01% -53.02%
EBITDA Margin
-1,836.47% -1,879.97% -2,654.42% -351.02%

Snapshot

Average Recommendation BUY Average Target Price 3,000.00
Number of Ratings 1 Current Quarters Estimate -0.01
FY Report Date 06 / 2026 Current Year's Estimate -0.58
Last Quarter’s Earnings -0.56 Median PE on CY Estimate N/A
Year Ago Earnings -1.85 Next Fiscal Year Estimate -0.02
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.01 -0.01 -0.58 -0.02
High Estimates -0.01 -0.01 -0.58 -0.02
Low Estimate -0.01 -0.01 -0.58 -0.02
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 0 0
OVERWEIGHT 0 0 0
HOLD 0 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Hold Hold

Helius Medical Technologies in the News